Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics.
Abdhish R
AR
Bhavsar
Cynthia R
CR
Stockdale
Frederick L
FL
Ferris
Alexander J
AJ
Brucker
Neil M
NM
Bressler
Adam R
AR
Glassman
D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000068258:Bevacizumab; D009877:Endophthalmitis / Q000453:epidemiology* / Q000517:prevention & control; D015818:Eye Infections, Bacterial / Q000453:epidemiology* / Q000517:prevention & control; D006801:Humans; D058449:Intravitreal Injections; D011206:Povidone-Iodine / Q000008:administration & dosage; D000069579:Ranibizumab; D012307:Risk Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000891:Anti-Infective Agents, Local; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D011206:Povidone-Iodine; D014222:Triamcinolone Acetonide; D000069579:Ranibizumab